The Leukemia & Lymphoma Society Mobilizes Influential Leaders across the Country in the Fight Against Blood Cancers
Hours expanded to 9 a.m. to 9 p.m.
CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients
If you're a member of the media, please direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) Western & Central New York Chapter to email@example.com or call our Chapter Office at 716.834.2578 or 800.784.2368, ext. 4663.